← Leaderboards
Kenneth H. Fife
Indiana Univ-Purdue Univ At Indianapolis
$1,137,888
Attributed
$1,137,888
Total exposure
19
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $312.5K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,137,888 · 19
By mechanism
M01$1,137,888 · 19
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Mitchell Goldman$10,867,864
- Joseph Wheat$0
- L Joseph Wheat$0
- Md Michael Frank$0
- Lawrence Joseph Wheat$1,178,559
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectAids TherapyHuman Therapy EvaluationDrug Screening /EvaluationClinical TrialsHiv InfectionsCombination ChemotherapyAntiaids AgentReverse Transcriptase InhibitorsLamivudineZidovudineHuman Immunodeficiency Virus 1Protease InhibitorVirus RnaFemaleBlood ChemistryIndinavirCase HistoryAids /Hiv DiagnosisWomen'S HealthPlacebosPatient /Disease RegistryStavudine
Grant awards (60)
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$69,967
M01 · FY2008 · RR · contact PI
A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE SYSTEM AND$4,543
M01 · FY2008 · RR · contact PI
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$293,476
M01 · FY2007 · RR · contact PI
A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE SYSTEM AND$19,057
M01 · FY2007 · RR · contact PI
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$216,369
M01 · FY2006 · RR · contact PI
PREVALENCE OF HPV DNA IN HIV INFECTED WOMEN WHO HAVE INITIATED HAART (A5029)$2,193
M01 · FY2006 · RR · contact PI
A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE SYSTEM AND$1,463
M01 · FY2006 · RR · contact PI
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$216,868
M01 · FY2005 · RR
HIV-INFECTED SUBJECTS WHO PARTICIPATED IN ACTG 388 &HAVE <200 HIV-1 RNA A5116$19,065
M01 · FY2005 · RR
DEPO-MEDROXYPROGESTERONE ACETATE AND SELECTED PROTEASE INHIBITOR$5,560
M01 · FY2005 · RR
EVALUATION OF METABOLIC COMPLICATIONS ASSOCIATED WITH ANTIRETROVIRAL MEDICATIONS$5,560
M01 · FY2005 · RR
PREVALENCE OF HPV DNA IN HIV INFECTED WOMEN WHO HAVE INITIATED HAART (A5029)$1,590
M01 · FY2005 · RR
Patient Evaluation for Potential AIDS Clinical Trial Participants$227,761
M01 · FY2004 · RR
HIV-Infected Subjects Who Participated in ACTG 388 &Have <200 HIV-1 RNA A5116$22,544
M01 · FY2004 · RR
DEPO-MEDROXYPROGESTERONE ACETATE AND SELECTED PROTEASE INHIBITOR...$19,433
M01 · FY2004 · RR
Prolongation of Viro.success, options for Viro.failure in HIV infected (ACTG372)$8,552
M01 · FY2004 · RR
EVALUATION OF METABOLIC COMPLICATIONS ASSOCIATED WITH ANTIRETROVIRAL MEDICATIONS$2,332
M01 · FY2004 · RR
Prevalence of HPV DNA in HIV infected women who have initiated HAART (A5029)$1,555
M01 · FY2004 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2002 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2002 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2002 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2002 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2002 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2002 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2001 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2001 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2001 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2001 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2001 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2001 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2000 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2000 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2000 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2000 · RR
PATIENT EVALUATION FOR POTENTIAL AIDS CLINICAL TRIAL PARTICIPANTS$0
M01 · FY2000 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2000 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2000 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2000 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2000 · RR
PHASE II STUDY OF THE PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0
M01 · FY2000 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2000 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2000 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2000 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2000 · RR
VIROLOGIC AND IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VERSUS DELAVIRDINE$0
M01 · FY2000 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2000 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2000 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2000 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2000 · RR
COMPARISON OF THE VIROLOGIC EFFICACY OF NULFINAVIR/DMP 266 IN COMBINATION$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2000 · RR
RANDOMIZED DOUBLE BLIND STUDY OF THE ANTIVIRAL ACTIVITY OF DIDANOSINE$0
M01 · FY2000 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2000 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2000 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2000 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2000 · RR
ORAL ISOTRETINOIN VS OBSERVATION FOR LOW GRADE CERVICAL DYSPLASIA IN$0
M01 · FY2000 · RR